Mercury Laboratories Limited
Mercury Laboratories Limited Fundamental Analysis
Mercury Laboratories Limited (MERCURYLAB.BO) shows weak financial fundamentals with a PE ratio of 20.56, profit margin of 6.18%, and ROE of 8.80%. The company generates $0.8B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 52.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze MERCURYLAB.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakMERCURYLAB.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentMERCURYLAB.BO trades at attractive valuation levels.
Growth Score
ModerateMERCURYLAB.BO shows steady but slowing expansion.
Financial Health Score
ExcellentMERCURYLAB.BO maintains a strong and stable balance sheet.
Profitability Score
WeakMERCURYLAB.BO struggles to sustain strong margins.
Key Financial Metrics
Is MERCURYLAB.BO Expensive or Cheap?
P/E Ratio
MERCURYLAB.BO trades at 20.56 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, MERCURYLAB.BO's PEG of -5.16 indicates potential undervaluation.
Price to Book
The market values Mercury Laboratories Limited at 1.74 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.21 times EBITDA. This is generally considered low.
How Well Does MERCURYLAB.BO Make Money?
Net Profit Margin
For every $100 in sales, Mercury Laboratories Limited keeps $6.18 as profit after all expenses.
Operating Margin
Core operations generate 16.84 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.80 in profit for every $100 of shareholder equity.
ROA
Mercury Laboratories Limited generates $6.37 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Mercury Laboratories Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Mercury Laboratories Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
MERCURYLAB.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
20.56
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-5.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.74
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.27
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.43
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How MERCURYLAB.BO Stacks Against Its Sector Peers
| Metric | MERCURYLAB.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 20.56 | 29.78 | Better (Cheaper) |
| ROE | 8.80% | 792.00% | Weak |
| Net Margin | 6.18% | -24634.00% (disorted) | Weak |
| Debt/Equity | 0.11 | 0.25 | Strong (Low Leverage) |
| Current Ratio | 3.43 | 4.60 | Strong Liquidity |
| ROA | 6.37% | -18106.00% (disorted) | Weak |
MERCURYLAB.BO outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Mercury Laboratories Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation